BioPharmSignal logoBioPharmSignal

Biotech News

Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update

Liquidia Corporation (LQDA)Liquidia Corporation2026-06-25 13:46 ESTEarnings

Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025 Received more than 2,800 unique patient prescriptions since launch in June 2025 Generated more than $30 million of positive cash flow during the fourth quarter 2025

Open original release

Related news

LQDALiquidia Corporation2026-06-25 13:46 EST

Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions

LQDALiquidia Corporation2026-06-25 13:46 EST

Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index

LQDALiquidia Corporation2026-06-25 13:46 EST

Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference

LQDALiquidia Corporation2026-06-25 13:46 EST

Liquidia Corporation Reports First Quarter 2026 Financial Results

LQDALiquidia Corporation2026-06-25 13:46 EST

Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update

LQDALiquidia Corporation2026-06-25 13:46 EST

Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences

LQDALiquidia Corporation2026-06-25 13:46 EST

Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference

LQDALiquidia Corporation2026-06-25 13:46 EST

Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress

LQDALiquidia Corporation2026-06-25 13:46 EST

Liquidia Corporation to Report Full Year 2025 Financial Results on March 5, 2026

LQDALiquidia Corporation2026-06-25 13:46 EST

Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

View all latest news

Liquidia Corporation

Liquidia is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

LQDALiquidia Corporation2026-06-26 09:31 EST

Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions

LQDALiquidia Corporation2026-06-26 09:31 EST

Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index

LQDALiquidia Corporation2026-06-26 09:31 EST

Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference

LQDALiquidia Corporation2026-06-26 09:31 EST

Liquidia Corporation Reports First Quarter 2026 Financial Results

LQDALiquidia Corporation2026-06-26 09:31 EST

Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States